Can Anteris Technologies Global (AVR) Stock Reach $14?

Key Takeaways

• The central price target is $14, the arithmetic mean of verified analyst targets from Cantor Fitzgerald ($15), TD Cowen ($15), Wells Fargo ($16), and Barclays ($10).
• At a recent price near $6.20, Anteris Technologies Global Corp. (AVR) would need to gain roughly 126% to reach $14 — a very large move for any equity.
• Individual targets span $10 to $16, with three firms at Buy or Overweight and Barclays initiating coverage at Hold.
• Supporting factors include a sharp expected revenue ramp, a substantial cash position, and a differentiated "biomimetic" heart-valve platform.
• Principal risks are deep operating losses, minimal revenue relative to market value, a premium valuation, and dependence on clinical and regulatory milestones.
• For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
• Investors seeking AI-driven ideas can also explore Trending AI Robots.

Analyst Price Targets and Consensus View

Anteris Technologies Global Corp. is a structural-heart medical-device company, not an ETF. Its lead product is the DurAVR transcatheter heart valve, a "biomimetic" valve designed to treat severe aortic stenosis (a narrowing of the heart's aortic valve that restricts blood flow) in a less invasive transcatheter procedure.

Coverage of the stock is thin but current. The most recent, individually attributable targets are Cantor Fitzgerald at $15 (Overweight), TD Cowen at $15 (Buy), Wells Fargo at $16 (Overweight), and Barclays at $10 (Hold, initiated by Matt Miksic in October 2026). Averaging those four figures yields a mean of $14, which matches the roughly $14 average reported by S&P Global and MarketBeat across a $10-to-$16 range. The central target used here is therefore $14.

The spread is wide for a stock this size, reflecting genuine disagreement about how quickly Anteris can convert clinical progress into commercial revenue. The bullish targets lean on the valve's differentiated design and an expected inflection in sales, while the more cautious Barclays view reflects the still-early commercial stage and ongoing losses.

Current Market Position and Path Toward the Target

AVR recently traded near $6.20, with a market capitalization of roughly $600 million. Reaching $14 implies an upside of about 126%, which is a very large required move. Notably, the stock has already shown outsized volatility — its 52-week range extends from about $3.30 to roughly $11.06 — so the path, if it materializes, would likely be uneven rather than linear.

Anteris is essentially pre-scale. Trailing-twelve-month revenue is only about $2.3 million against a net loss near $108 million and negative EPS (earnings per share) of roughly -$1.95. The investment case therefore rests on future execution rather than current profitability: analysts model revenue rising to roughly $7 million in 2026 and above $10 million in 2027, with the company holding about $233 million in cash to fund development.

What Could Support a Move Toward the Target

• Differentiated technology. DurAVR is engineered to mimic a healthy native aortic valve, a design distinction from competing transcatheter valves that could support adoption if clinical data remain positive.
• Revenue inflection. A projected jump from about $1.9 million in 2025 toward $7 million in 2026 would mark the beginning of commercial scaling, a catalyst analysts cite in their Buy ratings.
• Balance sheet. A cash position near $233 million provides runway to fund trials and commercialization without immediate dilution pressure.
• Analyst positioning. Four of the named firms rate the stock Buy or Overweight, with target revisions generally holding at or above $15.

What Could Prevent the Target From Being Reached

• Persistent losses. Negative EPS and a net loss near $108 million mean the company is not yet self-funding.
• Premium valuation. With minimal revenue, the stock trades at an elevated price-to-sales multiple, leaving little room for disappointment.
• Execution and regulatory risk. Clinical-trial outcomes, regulatory decisions, and commercial launch execution are binary-style risks for early-stage medical-device companies.
• Volatility. A 52-week range from $3.30 to $11.06 shows the shares can reprice sharply on single data points or financing news.

Technical Levels and Market Structure

The most relevant technical reference is the 52-week high near $11.06. A sustained move toward $14 would first require clearing that prior peak, making it a meaningful resistance zone. The $10 round-number level, which coincides with Barclays' target, also acts as a psychological marker. On the downside, the $5.50-to-$6.00 area has served as a recent consolidation zone, with the low near $3.30 representing a deeper support level. The long-term structure is best described as a high-volatility uptrend punctuated by sharp drawdowns.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, and the figures cited here are consistent with that convention, though individual firms may frame their outlooks differently. Investors should monitor quarterly earnings (the next results follow the company's November reporting cycle), any updates to full-year revenue guidance, clinical data releases and regulatory milestones for DurAVR, analyst target revisions, and cash-burn trajectory. No definitive forecast or timing should be inferred from the target itself.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Anteris, such tools can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual review alone. Traders interested in a systematic layer of analysis alongside fundamental research may find the signals a useful complement to their own process.

Final Assessment

The central target of $14 is the arithmetic mean of current analyst targets spanning $10 to $16. It represents a roughly 126% move from a recent price near $6.20 — a very large advance that hinges almost entirely on Anteris converting its DurAVR platform into accelerating commercial revenue. The strongest supports are a differentiated valve design, a projected revenue inflection, and a healthy cash balance; the principal obstacles are sustained losses, a premium valuation, and binary clinical and regulatory risks. Analyst disagreement is meaningful, and the target is an expectation, not a guarantee. Investors should focus on revenue execution, clinical data, and cash burn rather than the price level itself.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations